Keywords: Medivir, Meda, Valeant, Xerese, Elidel, hepres labialis

Medivir renegotiates deal with Meda, receiving $45 million for US rights for Xerese; Meda passes this and Elidel to Valeant

Article | 30 June 2011

Print This

Infectious disease specialist Medivir AB (OMX: MVIR) says that it has renegotiated the terms of its commercial partnership with fellow ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in